{"nctId":"NCT01384877","briefTitle":"Subcutaneous Lidocaine For Cancer-Related Pain","startDateStruct":{"date":"2011-12"},"conditions":["Cancer-related Pain"],"count":33,"armGroups":[{"label":"Lidocaine","type":"EXPERIMENTAL","interventionNames":["Drug: Lidocaine"]},{"label":"Placebo (D5W)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (D5W)"]}],"interventions":[{"name":"Lidocaine","otherNames":["Xylocaine","Lignocaine"]},{"name":"Placebo (D5W)","otherNames":["5% dextrose in water"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients 18 years of age or older\n* In or outpatients referred to the BCCA PSMPC Clinics with a diagnosis of cancer\n* Subjects must have somatic, visceral or neuropathic pain related to cancer\n* Pain intensity, measured by a worst pain score over the last 72 hours of ≥4 on a 0-10 numerical rating scale\n* Must have tried at least one opioid medication without adequate response or with significant side-effects for at least one week\n* For those with neuropathic pain, must have also tried at least one adjuvant analgesic, such as a tricyclic (unless contraindicated) or an anticonvulsant without adequate response or with significant side-effects for at least one week\n* Life expectancy of \\> 3 months\n* Must be able to communicate symptoms indicating potential toxicity of Lidocaine\n* Must have a competent caregiver in the home overnight after each infusion\n* Must be willing to remain within 30 minutes of the Cancer Centre during each infusion\n\nExclusion Criteria:\n\n* Clinically significant cardiac disease, i.e, cardiac failure, atrial fibrillation with slow ventricular rate (\\<60), any degree of heart block\n* New analgesic treatment initiated in time frame which might have effect within one week of study drug.\n* Hyper or hypokalemia.\n* Liver failure (bilirubin ≥ 25 umol/L).\n* Renal failure (eGFR \\<50% of normal)\n* Uncontrolled hypertension (\\>160/90).\n* Hypotension (systolic \\< 90).\n* Uncontrolled seizures.\n* Planned initiation of chemotherapy, radiotherapy or bisphosphonates within 30 days prior to treatment with study drug.\n* Received an investigational drug within 30 days prior to study.\n* History of allergy to lidocaine or other topical, local or infusional anesthetics.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Reduction in Worst Pain Intensity or Reduction in 24hr Opioid Dose of at Least 30% Without Worsening of Pain Scores","description":"The primary outcomes measure is a binary variable indicating whether lidocaine caused a reduction in cancer pain within 48 hours of infusion and lasting a minimum of 7 days. Lidocaine will be considered to have caused reduction in cancer pain if the subject had either one of the following episodes and lasting a minimum of 7 days:\n\n1. A 2-point reduction in severity of pain as assessed by the worst pain score in the last 24 hours (question 3) of the Brief Pain Inventory - Short Form (BPI), compared to the BPI pain score at baseline.\n\n   Or:\n2. ≥30% reduction in 24-hour opioid dose.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life Question: Over the Past 3 Days, Have You Been Affected by Pain?","description":"Effect of Lidocaine infusion on Quality Of Life parameters as measured by the Patient Outcome Scale (POS) Questionnaire Baseline scores were compared to an average post treatment score (taken immediately post treatment and on days 2, 3, and 7 following treatment) All POS questions were scored from 0 to 4 with lower scores requiring less clinical attention than higher scores","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"0.59"},{"groupId":"OG001","value":"2.67","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":".041"},{"groupId":"OG001","value":"2.52","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"0.54"},{"groupId":"OG001","value":"2.40","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Question: Over the Past 3 Days, Have Other Symptoms e.g. Feeling Sick, Having a Cough or Constipation Been Affecting How You Feel?","description":"Effect of Lidocaine infusion on Quality Of Life parameters as measured by the Patient Outcome Scale (POS) Questionnaire Baseline scores were compared to an average post treatment score (taken immediately post treatment and on days 2, 3, and 7 following treatment) All POS questions were scored from 0 to 4 with lower scores requiring less clinical attention than higher scores","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"1.36"},{"groupId":"OG001","value":"1.5","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.68"},{"groupId":"OG001","value":"1.29","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"1.79"},{"groupId":"OG001","value":"0.95","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Question: Over the Past 3 Days, Have You Been Feeling Anxious or Worried About Your Illness or Treatment?","description":"Effect of Lidocaine infusion on Quality Of Life parameters as measured by the Patient Outcome Scale (POS) Questionnaire Baseline scores were compared to an average post treatment score (taken immediately post treatment and on days 2, 3, and 7 following treatment) All POS questions were scored from 0 to 4 with lower scores requiring less clinical attention than higher scores","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"0.92"},{"groupId":"OG001","value":"1.67","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"0.67"},{"groupId":"OG001","value":"1.71","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"0.68"},{"groupId":"OG001","value":"1.47","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Question: Over the Past 3 Days, Have Any of Your Family or Friends Been Anxious or Worried About You?","description":"Effect of Lidocaine infusion on Quality Of Life parameters as measured by the Patient Outcome Scale (POS) Questionnaire Baseline scores were compared to an average post treatment score (taken immediately post treatment and on days 2, 3, and 7 following treatment) All POS questions were scored from 0 to 4 with lower scores requiring less clinical attention than higher scores","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"0.91"},{"groupId":"OG001","value":"1.67","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":"0.72"},{"groupId":"OG001","value":"1.71","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.62"},{"groupId":"OG001","value":"1.45","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Question: Over the Past 3 Days, Have You Been Able to Share How You Are Feeling With Your Family or Friends?","description":"Effect of Lidocaine infusion on Quality Of Life parameters as measured by the Patient Outcome Scale (POS) Questionnaire Baseline scores were compared to an average post treatment score (taken immediately post treatment and on days 2, 3, and 7 following treatment) All POS questions were scored from 0 to 4 with lower scores requiring less clinical attention than higher scores","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":"1.06"},{"groupId":"OG001","value":"1.33","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":"1.04"},{"groupId":"OG001","value":"1.32","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"1.06"},{"groupId":"OG001","value":"1.50","spread":"1.44"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Question: Over the Past 3 Days, Have You Been Feeling Depressed?","description":"Effect of Lidocaine infusion on Quality Of Life parameters as measured by the Patient Outcome Scale (POS) Questionnaire Baseline scores were compared to an average post treatment score (taken immediately post treatment and on days 2, 3, and 7 following treatment) All POS questions were scored from 0 to 4 with lower scores requiring less clinical attention than higher scores","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":"1.05"},{"groupId":"OG001","value":"1.25","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"1.00"},{"groupId":"OG001","value":"1.55","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":"0.83"},{"groupId":"OG001","value":"1.23","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Question: Over the Past 3 Days, Have You Felt Good About Yourself as a Person?","description":"Effect of Lidocaine infusion on Quality Of Life parameters as measured by the Patient Outcome Scale (POS) Questionnaire Baseline scores were compared to an average post treatment score (taken immediately post treatment and on days 2, 3, and 7 following treatment) All POS questions were scored from 0 to 4 with lower scores requiring less clinical attention than higher scores","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"0.96"},{"groupId":"OG001","value":"1.75","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"0.94"},{"groupId":"OG001","value":"1.52","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":"1.05"},{"groupId":"OG001","value":"1.37","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Question: Over the Past 3 Days, How Much Time do You Feel Has Been Wasted on Appointments Relating to Your Healthcare e.g. Waiting Around for Transport or Repeating Tests?","description":"Effect of Lidocaine infusion on Quality Of Life parameters as measured by the Patient Outcome Scale (POS) Questionnaire Baseline scores were compared to an average post treatment score (taken immediately post treatment and on days 2, 3, and 7 following treatment) All POS questions were scored from 0 to 4 with lower scores requiring less clinical attention than higher scores","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"1.23"},{"groupId":"OG001","value":"0.50","spread":"1.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"1.00"},{"groupId":"OG001","value":"0.77","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"0.87"},{"groupId":"OG001","value":"0.43","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Question: Over the Past 3 Days, Have Any Practical Matters Resulting From Your Illness, Either Financial or Personal, Been Addressed?","description":"Effect of Lidocaine infusion on Quality Of Life parameters as measured by the Patient Outcome Scale (POS) Questionnaire Baseline scores were compared to an average post treatment score (taken immediately post treatment and on days 2, 3, and 7 following treatment) All POS questions were scored from 0 to 4 with lower scores requiring less clinical attention than higher scores","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"1.04"},{"groupId":"OG001","value":"1.0","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.44"},{"groupId":"OG001","value":"1.12","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"1.41"},{"groupId":"OG001","value":"0.93","spread":"1.29"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["Tingling","Headache","Dysphagia","Shortness of Breath","Dysgeusia"]}}}